Biogen Quarterly Income Statement
NASDAQ: BIIBHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Biogen revenue and earnings
In the quarter ended Mar 31, 2026, Biogen generated $2.48 billion in revenue, up 1.9% from the same quarter a year earlier. Net income was $319.5 million (+32.8% year over year), for a net margin of 12.9% versus a median of 10.9% in the prior 5 quarters. Gross margin was 73.3% (down from 74.1%).
Diluted earnings per share came in at $2.15, up from $1.64.
Summary generated from market data by MetaCap's automated system. Methodology
Biogen income statement (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.48B | 2.28B | 2.53B | 2.65B | 2.43B | 2.45B | 2.47B | 2.46B | 2.29B | 2.39B | 2.53B | 2.46B |
| Revenue growth (YoY) | +1.93% | -7.14% | +2.79% | +7.33% | +6.13% | +2.87% | -2.55% | +0.36% | -7.00% | -6.20% | +0.87% | -5.14% |
| Cost of Revenue | 661.00M | 495.50M | 674.40M | 605.00M | 629.30M | 583.50M | 638.70M | 546.00M | 542.20M | 618.30M | 659.60M | 592.70M |
| Gross Profit | 1.82B | 1.78B | 1.86B | 2.04B | 1.80B | 1.87B | 1.83B | 1.92B | 1.75B | 1.77B | 1.87B | 1.86B |
| Research & Development | 539.00M | 509.40M | 436.10M | 399.00M | 434.10M | 513.30M | 516.20M | 505.40M | 445.40M | 554.30M | 736.30M | 584.20M |
| Selling, General & Admin | 607.30M | 682.50M | 594.80M | 583.80M | 572.50M | 680.00M | 588.40M | 553.80M | 581.50M | 608.50M | 788.20M | 548.00M |
| Interest Expense | 67.60M | 67.50M | 67.40M | 72.60M | 60.00M | 60.00M | 59.80M | 61.30M | 69.20M | 71.50M | 63.80M | 49.10M |
| Other Income (Expense) | -1.10M | -36.70M | 15.80M | -3.30M | 2.50M | 8.00M | -800.00K | -2.00M | -1.90M | 4.70M | -3.40M | -2.30M |
| Pretax Income | 377.70M | -56.00M | 557.30M | 744.00M | 311.20M | 291.50M | 451.00M | 698.70M | 464.80M | 291.60M | -141.20M | 708.10M |
| Income Tax | 58.20M | -7.10M | 90.80M | 109.20M | 70.70M | 24.80M | 62.50M | 115.10M | 71.40M | 42.70M | -72.90M | 114.80M |
| Net Income | 319.50M | -48.90M | 466.50M | 634.80M | 240.50M | 266.70M | 388.50M | 583.60M | 393.40M | 249.70M | -68.10M | 591.60M |
| Net Income growth (YoY) | +32.85% | -118.34% | +20.08% | +8.77% | -38.87% | +6.81% | — | -1.35% | +1.42% | -54.63% | -106.00% | -44.08% |
| EPS (Basic) | 2.17 | -0.33 | 3.18 | 4.33 | 1.65 | 1.82 | 2.67 | 4.01 | 2.71 | 1.71 | -0.47 | 4.09 |
| EPS (Diluted) | 2.15 | -0.35 | 3.17 | 4.33 | 1.64 | 1.82 | 2.66 | 4.00 | 2.70 | 1.70 | -0.47 | 4.07 |
| Shares Outstanding (Basic) | 147.20M | — | 146.60M | 146.50M | 146.10M | — | 145.70M | 145.60M | 145.20M | — | 144.80M | 144.70M |
| Shares Outstanding (Diluted) | 148.40M | — | 147.10M | 146.70M | 146.60M | — | 146.10M | 145.90M | 145.90M | — | 144.80M | 145.50M |
| Gross Margin | 73.32% | 78.26% | 73.39% | 77.13% | 74.11% | 76.23% | 74.10% | 77.85% | 76.33% | 74.09% | 73.93% | 75.87% |
| Net Margin | 12.89% | -2.15% | 18.40% | 24.00% | 9.89% | 10.86% | 15.76% | 23.68% | 17.18% | 10.46% | -2.69% | 24.09% |
This table shows 12 quarterly periods of Biogen's income statement, from Q1 2026 back to Q2 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BIIB's reporting calendar. What is a income statement?